ARTICLE | Distillery Therapeutics
Cancer
May 30, 2018 6:49 PM UTC
Patient sample and mouse studies suggest inhibiting IL-22 could help treat KRAS-mutant lung cancer. In KRAS-mutant lung adenocarcinoma patients, high tumor levels of the IL-22 receptor IL22RA1 were as...
BCIQ Company Profiles